Consensus Conference on a Composite Endpoint for Clinical Trials on Immunosuppressive Drugs in Lung Transplantation. - Université de Limoges Accéder directement au contenu
Article Dans Une Revue Transplantation Année : 2014

Consensus Conference on a Composite Endpoint for Clinical Trials on Immunosuppressive Drugs in Lung Transplantation.

Résumé

BACKGROUND: In lung transplantation, diverse clinical events may impact patient outcome. In clinical trials comparing intervention strategies, single primary endpoints require large populations, or long study durations, whereas composite endpoints (CEPs) do not take into account the respective impact of their components on patient survival. The objective of this study was to propose consensus recommendations on endpoints for clinical trials on immunosuppressants in lung transplantation. METHODS: The consensus process was managed through the Internet using the Delphi method. Forty experts were invited by the pilot group with the help of the International Society for Heart and Lung Transplantation and The Transplantation Society. In the first round, a questionnaire was made available to the experts to complete, and the responses were analyzed. In each next round, a new questionnaire was developed from the previous responses and sent to the panel members.

Dates et versions

hal-01092271 , version 1 (08-12-2014)

Identifiants

Citer

Caroline Monchaud, Benoît Marin, Marc Estenne, Pierre-Marie Preux, Pierre Marquet. Consensus Conference on a Composite Endpoint for Clinical Trials on Immunosuppressive Drugs in Lung Transplantation.. Transplantation, 2014, 98 (12), pp.1. ⟨10.1097/TP.0000000000000235⟩. ⟨hal-01092271⟩
67 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More